<DOC>
	<DOCNO>NCT02527785</DOCNO>
	<brief_summary>This study conduct phase II study triple combination oxaliplatin , irinotecan , S-1 first-line chemotherapy patient advance gastric cancer .</brief_summary>
	<brief_title>Study Oxaliplatin , Irinotecan , S-1 Gastric Cancer</brief_title>
	<detailed_description>It widely accept efficacy chemotherapy patient inoperable , advanced , metastatic gastric cancer well compare best supportive care . In general , combination chemotherapy efficient monotherapy reasonable give combination chemotherapy patient good performance status . Especially dual combination chemotherapy fluoropyrimidine platinum show objective response rate 25-48 % patient newly diagnose advanced metastatic gastric cancer several study triple combination oxaliplatin , irinotecan , fluoropyrimidine show response rate 53~75 % also high rate hematologic adverse event . So investigator conduct phase I study three drug modification dosage schedule conduct phase II study recommend dose triple chemotherapy phase I study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Pathologically confirm advanced , recurrent metastatic adenocarcinoma stomach ( stage IV primary tumor , regional node , metastasis ( TNM ) stag system ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 More 3 month expect life span Measurable lesion RECIST criterion version 1.1 Palliative chemotherapy naive Adequate organ function Participants must sign informed consent indicate aware investigational nature study keep policy hospital Positive Her2 status participant ' cancer tissue . Any prior 2 year concurrent malignancy nonmelanoma skin cancer , situ cancer uterine cervix , papillary follicular thyroid cancer . Participants receive radiation therapy target lesion 4 week study enrollment Participants receive major surgery 4 week study enrollment Participants active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , myocardial infarction precede 12 month , pregnancy , breast feeding Participants central nervous system ( CNS ) metastases Participants peripheral sensory neuropathy impair functional activity Participants gastrointestinal obstruction bleed induce malabsorption oral chemotherapeutic agent .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stomach neoplasm</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>S-1</keyword>
</DOC>